Start Date
August 31, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
radiolabeled DPTA-omburtamab
Biological, radiolabeled DPTA-omburtamab
Memorial Sloan Kettering Cancer Center, New York
Johns Hopkins, Baltimore
Duke Cancer Center, Durham
M.D. Anderson Cancer Center, Houston
Cedars-Sinai Medical Center, Los Angeles
The University of Washington, Seattle
The Christie Hospital NHS Foundation Trust, Manchester
The Royal Marsden Hospital, Sutton
Lead Sponsor
Y-mAbs Therapeutics
INDUSTRY